Long-term outcome of cyclosporin rescue therapy in acute, steroid-refractory severe ulcerative colitis

Tamás Molnár, Klaudia Farkas, Zoltán Szepes, Ferenc Nagy, Mónika Szűcs, Tibor Nyári, Anita Bálint and Tibor Wittmann

United European Gastroenterology Journal
2014, Vol. 2(2) 108–112
© Author(s) 2014
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2050640614520865
ueg.sagepub.com

Abstract

Background: Although cyclosporin is effective in severe ulcerative colitis (UC), long-term colectomy rate varies between 60 and 88% among patients in whom cyclosporin initially induced remission. The aim of our study was to evaluate the long-term outcome and the optimal duration of cyclosporin therapy in acute, severe UC.

Methods: A total of 73 patients underwent i.v. cyclosporin therapy for a steroid refractory flare up of UC between 1998 and 2009. All patients were treated with 1 mg/kg i.v. methylprednisolone for 3–7 days before the administration of cyclosporin. Patients received i.v. cyclosporin of 4–5 mg/kg for 5 days following oral treatment.

Results: The mean follow up after the initiation of cyclosporin was 4.2 years. There were 20 patients who underwent early colectomy. Cyclosporin had to be discontinued due to side effects in 22 patients. Cyclosporin failed and late colectomy was performed in 14 of the 53 responders. Duration of cyclosporin treatment was significantly longer in those who avoided colectomy. The probability of avoiding colectomy proved to be 66% in case of 1-year treatment period with cyclosporin. The longer treatment period resulted in longer colectomy-free disease course.

Conclusions: Cyclosporin is effective in acute, severe UC during long-term follow up. Our data suggest that the longer cyclosporin is used, the more it is possible to avoid colectomy in the future.

Keywords

Colectomy, cyclosporin, long-term efficacy, safety, ulcerative colitis

Received: 23 August 2013; accepted: 26 December 2013

Introduction

The main goal of treatment of ulcerative colitis (UC) is to induce and maintain steroid-free remission, improve the quality of life, and reduce the risks of colectomy. Corticosteroids have been the primary therapies in moderate to severe UC for years. Those who fail to respond to treatment with corticosteroids, or who present with severely active UC, should be considered as candidates for rescue treatment.¹ Our previous work revealed that anaemia, need for blood transfusion, and frequency of previous hospitalizations significantly determines the response to early parenteral corticosteroid therapy. Colectomy rate was 2.5-times higher in patients refractory to i.v. steroid therapy, which may determine both the early and late outcome and the colectomy rate of acute, severe UC.²

Cyclosporin is one of the most effective therapeutic choice in patients with severe UC; however, long-term

colectomy rate still varies between 60–88% among patients in whom cyclosporin initially induced remission.³ The early disappointing long-term results and the serious side effects limit the widespread use of cyclosporin in the era of infliximab; however, it serves as a rapidly acting ‘bridge’ to maintenance therapy with the slowly acting agents azathioprine or mercaptopurine.⁴ Although the optimal duration of cyclosporin treatment is unknown, it is usually discontinued within 3 months.⁵

Since data on long-term efficacy of cyclosporin are still controversial and the optimal duration of therapy

University of Szeged, Szeged, Hungary

Corresponding author:

Tamás Molnár, First Department of Medicine, University of Szeged. 8–10 Koranyi fasor, Szeged, H6720, Hungary.
Email: molnar.tamas@med.u-szeged.hu

is unknown the aim of our study was to retrospectively evaluate the long-term efficacy and safety of cyclosporin therapy in patients with acute, steroid-refractory severe UC.

Patients and methods

Patient population

All patients who underwent i.v. cyclosporin therapy in our tertiary clinic for a steroid refractory flare up of severe UC between January 1998 and June 2009 were identified from our database. Definition of steroid refractoriness was set up according to the ECCO guideline.⁶ A total of 73 patients (40 females, 33 males; mean age at diagnosis 31.7 years, mean disease duration 13.4 years) fulfilled the inclusion criteria. The patients' medical records were collected continuously in an IBD database developed by us. The median Lichtiger score was 12 (interquartile range 9–14) at the start of cyclosporin therapy. Data were analysed retrospectively in September 2012. We reviewed the age, gender, disease duration, disease extent, concomitant azathioprine/mercaptopurine use, the dose and duration of cyclosporin therapy, the frequency of side effects, the need for infliximab therapy after discontinuation of cyclosporin, and the frequency of colectomy. The demographics of the patients are detailed in Table 1. Twenty-seven patients received thiopurine therapy before the administration of cyclosporin. The mean length of follow up was 4.2 years. Cyclosporin was stopped in case of clinical remission, intolerable side effects or loss of response. Disease activity was regularly defined by Lichtiger score. Lichtiger score ≤ 2 was considered remission.

Table 1. Demographics of the patients

Characteristic	Ulcerative colitis (n = 73)
Age at diagnosis (years)	44.6 (22–74)
Disease duration (years)	13.4 (3–42)
Gender (female/male)	40/33
Left-sided colitis/extensive colitis	28/45
Concomitant azathioprine or mercaptopurine	27
Body mass index (kg/m ²)	23.6 (15.2–38.3)
Dose of cyclosporin (mg/kg)	4.7
Length of follow up (years)	4.2

Values are mean (range), n, or mean.

Administration of cyclosporin

All patients were treated with 1 mg/kg i.v. methylprednisolone for 3–7 days before the administration of cyclosporin. Patients received i.v. cyclosporin of 4–5 mg/kg for 5 days following oral treatment at the same starting dose in the case of a good initial response. Cyclosporin levels were closely monitored, and the dose was adjusted to maintain fasting levels between 150 and 300 ng/ml and 2 hours post-dosing level of 800–1200 ng/ml. When starting cyclosporin therapy, we planned to use it at least for 6 months.

Twenty-seven patients received concomitant immunosuppression (26 thiopurines, one mycophenolate mofetil) before cyclosporin therapy. None of the patients was treated with infliximab before cyclosporin therapy.

Statistical analysis

Data analysis was carried out using Student t-test and Wilcoxon test. Proportions were analysed using Pearson's chi-squared test, Fisher's exact test. Kaplan–Meier survival curves were plotted for analysis with the log-rank and Breslow tests. Cox regression was applied to investigate the relationship between the cyclosporin treatment period and the risk of colectomy. $p < 0.05$ was considered statistically significant. For statistical analysis, SPSS version 15.0 (SPSS, Chicago, IL, USA) was used.

Results

Short and long-term efficacy of cyclosporin therapy

In this study, 53/73 (73%) patients initially responded to i.v. cyclosporin. Twenty (27%) patients underwent early colectomy within 3 months. During the >4-year follow-up period, 14 of the 53 responder patients (26%) underwent late colectomy. Cyclosporin had to be discontinued because of intolerable or severe side effects in 22/53 (42%) patients. The mortality rate was 0%. Overall, colectomy free survival was 53%. Five patients were switched to infliximab after cyclosporin failure. For maintenance therapy, azathioprine was given for 24 patients, 5-aminosalicylic acid for 18 patients, and infliximab for seven patients who avoided colectomy.

Figure 1 shows the outcomes of the rescue cyclosporin therapy in acute, severe UC patients. The demographic and clinical data of patients who underwent and who avoided surgery are detailed in Table 2.

Duration of cyclosporin therapy

Duration of cyclosporin therapy was significantly shorter in those responder patients who underwent late colectomy vs. those who avoided surgery (5.4 vs. 13.3 months, $p=0.009$; Figure 2). If patients were treated for a year, the probability of avoiding colectomy proved to be 66%. The longer treatment period decreased the risk of colectomy in the Cox regression model (hazard rate ratio 0.98, $p=0.013$). The mean time elapsed between the discontinuation of cyclosporin therapy and colectomy was 9 months (0.1–72 months). Patients who underwent late colectomy were operated on an average of 22 months after stopping cyclosporin. Cyclosporin was discontinued because of side effects in 53% of these patients and because of loss

of response in 43%. Patients who avoided colectomy were in remission, defined as Lichtiger score ≤ 2 , for an average of 12.7 months before stopping cyclosporin. Of these patients, azathioprine was given for 24 and infliximab for seven patients for maintaining remission after the cyclosporin therapy.

Side effects

The types of major side effects occurring during cyclosporin therapy are summarized in Table 3. Side effects occurred in 52 patients (72%) during the therapy. The most frequent side effects were hypertension (21%), tremor (19%), hypertrichosis (14%), myalgia and muscle cramping (15 and 6%), and numbness of legs (8%). Nephro- or hepatotoxicity occurred in seven

Figure 1. Outcomes of the rescue cyclosporin therapy in acute, severe UC patients.

Table 2. Demographic and clinical data of patients

Characteristic	Colectomized ($n=34$)	Colectomy free ($n=39$)
Age at diagnosis (years)	32.4 (14–69)	31.3 (16–63)
Disease duration (years)	12.8 (3–42)	14 (3–36)
Gender (female/male)	19/15	20/19
Left-sided colitis/extensive colitis	10/24	20/19
Concomitant azathioprine/mercaptopurine	12	15
Body mass index (kg/m^2)	22.2 (15.2–33.3)	24.9 (16–38.2)
Duration of cyclosporin therapy (months)	5.4 (0.1–41)	13.3 (0.1–60)
Side effects	19	18

Values are mean (range), n , or mean.

Figure 2. Kaplan-Meier plot showing the need for colectomy in relation to the duration of cyclosporin therapy.

Table 3. Major side effects occurring during cyclosporin therapy

Type of side effects	Patients (n = 37)
Disturbance of sensation	2
Gastrointestinal side effects	3
Liver function abnormalities	3
Gingivitis, gingiva hyperplasia	3
Numbness of extremities	4
Myalgia	4
Alopecia	5
Hypertrichosis	8
Tremor, muscle spasm	11
Hypertension	11

Values are n.

patients (14%). Increased serum cholesterol levels were detected in 47.2% of the patients. The major side effects resulting in the discontinuation of cyclosporin therapy occurred in 22 patients. The most frequent were musculoskeletal adverse reactions (47%) and hypertension (42%), then neurological side effects (37%), gastrointestinal side effects (26%), skin side effects (16%), and malaise (5%).

Discussion

This retrospective study confirmed that cyclosporin is effective in the treatment of acute, severe UC during the long-term follow up. Overall, colectomy free survival was 53% during the >4-year follow-up period. Colectomy-free survival significantly increased in case of longer duration of cyclosporin therapy. If patients were treated for a year, the probability to avoid colectomy proved to be 66%.

The published data about the short and long-term results of cyclosporin therapy are various and controversial – maybe due to the small patient numbers and the difference in the duration of therapy. Recently, some studies tried to obtain a coherent view and examined the long-term outcome of cyclosporin therapy. In the study of Mocciaro et al.⁷ the colectomy rate was 29% at 3 months and 48% at 12 months in 35 cyclosporin-treated UC patients. The 2–3-year cumulative colectomy rates were 54% and 57%. In this study, cyclosporin was administered for a maximum of 3 months. Data from the UK revealed 42% of UC patients undergoing colectomy during a median follow up of 3.8 years.⁸ In a Japanese study, the overall percentages of patients who had not required surgery were 72% at 1 year, 62% at 2 years, 58% at 3 years, and 48% at 5 years.⁹ Unfortunately, these papers do not clarify the duration of cyclosporin therapy.

Cheifetz et al.¹⁰ treated 71 patients with cyclosporin and followed them up for a mean of 3 years. Cumulative colectomy rates were 39% at 1 year, 42% at 2 years, and 46% at 5 years. Cyclosporin was discontinued in most patients by 6 months.

In general, cyclosporin is used for inducing remission as a rescue therapy and the optimal duration of the therapy is unknown.¹¹ In our study, the colectomy rate after 4 years was 47%. The mean duration of cyclosporin therapy was more than 13 months in colectomy-free patients. Our results showed that two-thirds of patients can avoid colectomy if treated with cyclosporin for at least 12 months. In a recent paper of Sjöberg et al.,¹² cyclosporin was given for a mean of 4.5 months: at 12 months, 77% of the patients remained colectomy-free; however, this study was not followed up for more than 1 year.

Concerns of toxicity remain the main reasons for underusing cyclosporin in the clinical practice. However, all of the studies mentioned above found the majority of the adverse events to be mild. Sternthal et al.¹³ revealed major adverse events in 15% of their patients. Nephrotoxicity occurred in 5% of the patients. Serious infection occurred in 6%, seizures in 4%, anaphylaxis in 1%, and death in 2%. The most common minor adverse events were paresthesias, hypomagnesemia, hypertension, and hypertrichosis.¹³ In our study, more than 70% of patients developed mild or moderate side effects and 60% of them resulted in the discontinuation of the therapy.

The main limitation of this study is the retrospective nature. However, the data compared in the study are quite reliable and they come from a single centre with an interest in the management of severe UC.

In summary, our data show similar long-term outcome of cyclosporin therapy than the recent studies. Cyclosporin seems to be effective in acute, severe UC during long-term follow up. Although the optimal duration for the treatment is unknown, our data suggest that the longer cyclosporin is used, the more it is possible to avoid colectomy in the future. Multicentre trials would be needed to confirm the optimal duration for cyclosporin.

Funding

This work was supported by OTKA (research proposal PD 105948; PI: Klaudia Farkas) and TÁMOP (4.2.2.A-11/1/KONV-2012-0035, 4.2.2.A-11/1/KONV-2012 0052, and 4.2.2.A-11/1/KONV-2012-0073).

Conflict of interest

The authors declare that there is no conflict of interest.

References

1. Hoentjen F, Sakuraba A and Hanauer S. Update on management of ulcerative colitis. *Curr Gastroenterol Rep* 2011; 13: 475–485.
2. Molnar T, Farkas K, Nyari T, et al. Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients. *J Gastrointest Liver Dis* 2011; 20: 359–363.
3. Moskovitz DN, Van Assche G, Maenhout, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. *Clin Gastroenterol Hepatol* 2006; 4: 760–765.
4. Rolny P and Vatn M. Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article. *Scand J Gastroenterol* 2012; 48: 131–135.
5. Loftus CG, Loftus EV and Sandborn WJ. Cyclosporin for refractory ulcerative colitis. *Gut* 2003; 52: 172–173.
6. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. *J Crohns Colitis* 2008; 2: 1–23.
7. Mocciano F, Renna S, Orlando A, et al. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. *J Crohns Colitis* 2012; 6: 681–686.
8. Sharkey L, Bredin F, Nightingale A, et al. The use of Cyclosporine A in acute steroid-refractory ulcerative colitis: long term outcomes. *J Crohns Colitis* 2011; 5: 91–94.
9. Kobayashi T, Naganuma M, Okamoto S, et al. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. *J Gastroenterol* 2010; 45: 1129–1137.
10. Cheifetz AS, Stern J, Garud S, et al. Cyclosporine is safe and effective in patients with severe ulcerative colitis. *J Clin Gastroenterol* 2011; 45: 107–112.
11. Travis SPL, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. *J Crohns Colitis* 2008; 2: 24–62.
12. Sjöberg M, Walch A, Meshkat M, et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: A retrospective observational study. *Inflamm Bowel Dis* 2012; 18: 212–218.
13. Sternthal MB, Murphy SJ, George J, et al. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. *Am J Gastroenterol* 2008; 103: 937–943.